Basilea Pharmaceutica Croissance future

Future contrôle des critères 5/6

Basilea Pharmaceutica devrait augmenter ses bénéfices et son chiffre d'affaires de 20.1% et de 6% par an respectivement. Le BPA devrait croître de de 20.2% par an. Le rendement des capitaux propres devrait être 83.8% dans 3 ans.

Informations clés

20.1%

Taux de croissance des bénéfices

20.2%

Taux de croissance du BPA

Biotechs croissance des bénéfices	42.7%
Taux de croissance des recettes	6.0%
Rendement futur des capitaux propres	83.8%
Couverture par les analystes	Low
Dernière mise à jour	15 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Mar 24

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Feb 18

Prévisions de croissance des bénéfices et des revenus

SWX:BSLN - Estimations futures des analystes et données financières antérieures (CHF Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	249	74	59	58	3
12/31/2025	222	46	54	49	5
12/31/2024	205	61	59	57	4
6/30/2024	149	-1	9	10	N/A
3/31/2024	153	5	11	12	N/A
12/31/2023	158	10	13	14	N/A
9/30/2023	166	33	20	22	N/A
6/30/2023	175	56	27	29	N/A
3/31/2023	161	34	16	18	N/A
12/31/2022	148	12	4	7	N/A
9/30/2022	150	6	-2	1	N/A
6/30/2022	152	1	-8	-5	N/A
3/31/2022	150	-3	-20	-18	N/A
12/31/2021	148	-7	-33	-32	N/A
9/30/2021	130	-26	-41	-40	N/A
6/30/2021	112	-45	-50	-48	N/A
3/31/2021	120	-30	-53	-51	N/A
12/31/2020	128	-15	-56	-54	N/A
9/30/2020	134	-6	-55	-53	N/A
6/30/2020	141	3	-53	-52	N/A
3/31/2020	137	-10	-58	-58	N/A
12/31/2019	134	-22	-64	-64	N/A
9/30/2019	135	-23	-64	-64	N/A
6/30/2019	136	-24	-65	-64	N/A
3/31/2019	134	-28	-72	-72	N/A
12/31/2018	133	-31	-80	-79	N/A
9/30/2018	124	-26	-43	-42	N/A
6/30/2018	115	-21	-6	-5	N/A
3/31/2018	108	-20	N/A	7	N/A
12/31/2017	102	-19	N/A	19	N/A
9/30/2017	92	-32	N/A	-19	N/A
6/30/2017	82	-44	N/A	-58	N/A
3/31/2017	74	-48	N/A	-66	N/A
12/31/2016	66	-51	N/A	-75	N/A
9/30/2016	62	-55	N/A	-89	N/A
6/30/2016	58	-59	N/A	-102	N/A
3/31/2016	55	-61	N/A	-85	N/A
12/31/2015	53	-62	N/A	-68	N/A
9/30/2015	50	-57	N/A	-57	N/A
6/30/2015	47	-52	N/A	-46	N/A
3/31/2015	45	-47	N/A	-59	N/A
12/31/2014	42	-42	N/A	-71	N/A
9/30/2014	42	-38	N/A	-71	N/A
6/30/2014	41	-35	N/A	-71	N/A
3/31/2014	41	-34	N/A	-65	N/A
12/31/2013	41	-33	N/A	-59	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: BSLN devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 0.3% ).

Bénéfices vs marché: BSLN devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: BSLN devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de BSLN ( 6% par an) devrait croître plus rapidement que le marché Swiss ( 4.2% par an).

Croissance élevée des revenus: Le chiffre d'affaires de BSLN ( 6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de BSLN devrait être très élevé dans 3 ans ( 83.8 %).

Basilea Pharmaceutica Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Basilea Pharmaceutica AG Updates Financial Guidance for the Year 2024

Consensus EPS estimates increase by 15%

Price target increased by 7.6% to CHF70.58

Consensus EPS estimates fall by 78%

Price target decreased by 7.6% to CHF69.90

Consensus EPS estimates fall by 30%

Recent updates

Basilea Pharmaceutica AG Updates Financial Guidance for the Year 2024

European Commission Approves the Pediatric Use of Basilea Pharmaceutica AG's Antifungal Cresemba® (Isavuconazole)

First half 2024 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Consensus EPS estimates increase by 15%

Price target increased by 7.6% to CHF70.58

Basilea Pharmaceutica AG to Report First Half, 2024 Results on Aug 13, 2024

New minor risk - Negative shareholders equity

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 78%

Price target decreased by 7.6% to CHF69.90

Consensus EPS estimates fall by 30%

Basilea Pharmaceutica AG to Report Fiscal Year 2023 Results on Feb 13, 2024

Basilea Pharmaceutica AG, Annual General Meeting, Apr 24, 2024

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Basilea Pharmaceutica AG Revises Earnings Guidance for the Year 2023

First half 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Price target decreased by 9.0% to CHF67.18

Consensus EPS estimates increase by 13%

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Basilea Pharmaceutica AG to Report First Half, 2023 Results on Aug 15, 2023

Basilea Pharmaceutica Ltd Revises Earnings Guidance for the Year 2022

Basilea Pharmaceutica AG, Annual General Meeting, Apr 26, 2023

Basilea Pharmaceutica AG to Report Fiscal Year 2022 Results on Feb 14, 2023

Price target decreased to CHF68.58

Price target decreased to CHF68.58

Basilea Pharmaceutica AG 's ERADICATE Phase 3 Study Results Highlight the Potential Role of Ceftobiprole in the Treatment of Staphylococcus Aureus Bacteremia (Sab)

Consensus estimates of losses per share improve by 13%

Consensus estimates of losses per share improve by 10%

Basilea Pharmaceutica AG Revises Earnings Guidance for the Full Year 2022

Price target increased to CHF73.98

First half 2022 earnings: EPS and revenues exceed analyst expectations

Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022

Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Consensus forecasts updated

Basilea Pharmaceutica Ltd. Positive Results of Phase 3 Eradicate Study with Ceftobiprole in Staphylococcus Aureus Bacteremia

Basilea Pharmaceutica AG Reports Progress on the Implementation of Its Strategy to Focus on Anti-Infectives

Basilea Pharmaceutica AG to Report First Half, 2022 Results on Aug 16, 2022

High number of new directors

Price target decreased to CHF77.00

Insufficient new directors

Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Board and as Chairman of the Audit Committee

Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891

Price target decreased to CHF77.50

Basilea Reports Preclinical Data on Anti-Cancer Activity of Novel Oncology Drug Candidate BAL0891 at ESMO TAT congress

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Basilea Pharmaceutica AG Provides Earnings Guidance for the Fiscal Year 2022

Basilea Reports Updated Interim Results for iCCA Patients with FGFR2 Mutations and Amplifications from Phase 2 Study FIDES-01 at ASCO GI Cancers Symposium

Basilea Announces Completion of Patient Enrolment in Phase 3 Eradicate Study Investigating Ceftobiprole in Bloodstream Infections

Forecast to breakeven in 2024

Basilea Pharmaceutica Ltd. Announces FDA Approval of Investigational New Drug Application for Novel Oncology Drug Candidate BAL0891

Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Derazantinib in Patients with FGFR2 Fusion-Positive iCCA at ESMO Congress

First half 2021 earnings released: CHF1.72 loss per share (vs CHF0.92 profit in 1H 2020)

No longer forecast to breakeven

Basilea Pharmaceutica Ltd. Provides Updates on Efficacy Data with Derazantinib in Bile Duct Cancer and on Ongoing Clinical Programs in Urothelial and Gastric Cancer

Basilea Pharmaceutica AG Wins Carb-X Grant of Up to USD 2.7 Million to Develop Novel-Class Antibiotic

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Basilea Pharmaceutica AG has completed a Follow-on Equity Offering in the amount of CHF 45.75 million.

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

PHT International Inc. entered into an agreement to acquire Basilea Pharmaceutica China Ltd. from Basilea Pharmaceutica AG (SWX:BSLN) for $6.3 million.

Basilea Pharmaceutica Ltd. Reports derazantinib/PD-L1 Checkpoint Inhibitor Combination Results from Dose-Finding Part of FIDES-02 Study in Patients with Solid Tumors at ASCO GU Symposium

Basilea Pharmaceutica Ltd. Promotes Potential First-In-Class Small-Molecule Kinase Inhibitor